These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1968 related items for PubMed ID: 29224108

  • 1. Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.
    Traish AM.
    Adv Exp Med Biol; 2017; 1043():473-526. PubMed ID: 29224108
    [Abstract] [Full Text] [Related]

  • 2. Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It's Time to Sound the Alarm.
    Traish AM.
    World J Mens Health; 2020 Jul; 38(3):323-337. PubMed ID: 32202088
    [Abstract] [Full Text] [Related]

  • 3. Benefits and Health Implications of Testosterone Therapy in Men With Testosterone Deficiency.
    Traish AM.
    Sex Med Rev; 2018 Jan; 6(1):86-105. PubMed ID: 29128268
    [Abstract] [Full Text] [Related]

  • 4. Characteristics of Men Who Report Persistent Sexual Symptoms After Finasteride Use for Hair Loss.
    Basaria S, Jasuja R, Huang G, Wharton W, Pan H, Pencina K, Li Z, Travison TG, Bhawan J, Gonthier R, Labrie F, Dury AY, Serra C, Papazian A, O'Leary M, Amr S, Storer TW, Stern E, Bhasin S.
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4669-4680. PubMed ID: 27662439
    [Abstract] [Full Text] [Related]

  • 5. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G, Rittmaster RS, Klocker H.
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [Abstract] [Full Text] [Related]

  • 6. Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?
    Traish AM, Melcangi RC, Bortolato M, Garcia-Segura LM, Zitzmann M.
    Rev Endocr Metab Disord; 2015 Sep; 16(3):177-98. PubMed ID: 26296373
    [Abstract] [Full Text] [Related]

  • 7. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G, Rittmaster RS, Klocker H.
    World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
    [Abstract] [Full Text] [Related]

  • 8. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.
    Corona G, Tirabassi G, Santi D, Maseroli E, Gacci M, Dicuio M, Sforza A, Mannucci E, Maggi M.
    Andrology; 2017 Jul; 5(4):671-678. PubMed ID: 28453908
    [Abstract] [Full Text] [Related]

  • 9. Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction.
    Traish A, Haider KS, Doros G, Haider A.
    Horm Mol Biol Clin Investig; 2017 Jun 21; 30(3):. PubMed ID: 28632494
    [Abstract] [Full Text] [Related]

  • 10. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
    Andriole G, Bruchovsky N, Chung LW, Matsumoto AM, Rittmaster R, Roehrborn C, Russell D, Tindall D.
    J Urol; 2004 Oct 21; 172(4 Pt 1):1399-403. PubMed ID: 15371854
    [Abstract] [Full Text] [Related]

  • 11. Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation.
    Gur S, Kadowitz PJ, Hellstrom WJ.
    Expert Opin Drug Saf; 2013 Jan 21; 12(1):81-90. PubMed ID: 23173718
    [Abstract] [Full Text] [Related]

  • 12. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.
    Amaral C, Varela C, Correia-da-Silva G, Tavares da Silva E, Carvalho RA, Costa SC, Cunha SC, Fernandes JO, Teixeira N, Roleira FM.
    Biochimie; 2013 Nov 21; 95(11):2097-106. PubMed ID: 23933094
    [Abstract] [Full Text] [Related]

  • 13. The dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depression.
    Traish AM, Mulgaonkar A, Giordano N.
    Korean J Urol; 2014 Jun 21; 55(6):367-79. PubMed ID: 24955220
    [Abstract] [Full Text] [Related]

  • 14. Finasteride, a Type 2 5alpha-reductase inhibitor, in the treatment of men with androgenetic alopecia.
    Kaufman KD, Dawber RP.
    Expert Opin Investig Drugs; 1999 Apr 21; 8(4):403-15. PubMed ID: 15992088
    [Abstract] [Full Text] [Related]

  • 15. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis.
    Lee S, Lee YB, Choe SJ, Lee WS.
    Acta Derm Venereol; 2019 Jan 01; 99(1):12-17. PubMed ID: 30206635
    [Abstract] [Full Text] [Related]

  • 16. The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men's Health.
    Said MA, Mehta A.
    Curr Urol Rep; 2018 Jun 16; 19(8):65. PubMed ID: 29909472
    [Abstract] [Full Text] [Related]

  • 17. Diagnosis and Treatment of Testosterone Deficiency: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015).
    Khera M, Adaikan G, Buvat J, Carrier S, El-Meliegy A, Hatzimouratidis K, McCullough A, Morgentaler A, Torres LO, Salonia A.
    J Sex Med; 2016 Dec 16; 13(12):1787-1804. PubMed ID: 27914560
    [Abstract] [Full Text] [Related]

  • 18. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone.
    Anderson RA, Wallace AM, Wu FC.
    J Clin Endocrinol Metab; 1996 Mar 16; 81(3):902-8. PubMed ID: 8772548
    [Abstract] [Full Text] [Related]

  • 19. Testosterone therapy in men with testosterone deficiency: are the benefits and cardiovascular risks real or imagined?
    Traish AM.
    Am J Physiol Regul Integr Comp Physiol; 2016 Sep 01; 311(3):R566-73. PubMed ID: 27488887
    [Abstract] [Full Text] [Related]

  • 20. Inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction.
    Corona G, Rastrelli G, Maseroli E, Balercia G, Sforza A, Forti G, Mannucci E, Maggi M.
    J Endocrinol Invest; 2012 Nov 01; 35(10):915-20. PubMed ID: 22777612
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 99.